A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 9, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Cutaneous T-Cell Lymphoma/Mycosis FungoidesCutaneous T Cell Lymphoma
Interventions
OTHER

molecular subtype based treatment

The immunohistochemistry algorithm established by the previous research group was used to determine the molecular subtype, and the corresponding treatment plan was selected according to the subtype. Such as for TCyEM patients, interferon-based immunomodulatory therapy was selected, and TCM-type patients were treated with retinoids.

Trial Locations (3)

100034

RECRUITING

Peking University First Hospital, Beijing

100142

RECRUITING

Beijing Cancer Hospital, Beijing

100191

RECRUITING

Peking University Third Hospital, Beijing

All Listed Sponsors
collaborator

Peking University Third Hospital

OTHER

collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

Peking University First Hospital

OTHER